BNB Plus Corp.

BNBX

US03815U6073

Investment Management & Fund Operators

Delayed OTC Markets Other stock markets 15:23:49 2026-07-22 EDT			5-day change	1st Jan Change
0.1100 ^USD	+37.33%		-16.67%	-91.06%

07-15	BNB Plus Corp.(OTCPK:BNBX) dropped from S&P TMI Index	CI
07-13	BNB Plus Receives Nasdaq Delisting Notice, Plans OTC Listing	MT

Top Premarket Decliners

Published on 09/30/2025 at 08:16 am EDT

MT Newswires

Add MarketScreener to your sources

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Add MarketScreener to your sources

Latest news about BNB Plus Corp.

07-15	BNB Plus Corp.(OTCPK:BNBX) dropped from S&P TMI Index	CI
07-13	BNB Plus Receives Nasdaq Delisting Notice, Plans OTC Listing	MT
07-12	BNB Plus Corp.(OTCPK:BNBX) dropped from NASDAQ Composite Index	CI
05-25	BNB Plus Corp. announced that it expects to receive $5 million in funding from Silvermine Capital Advisors, LLC, Off The Chain Capital, LLC	CI
05-15	BNB Plus Corp. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
04-20	BNB Plus Corp Announces Review of Strategic Alternatives to Maximize Shareholder Value	CI
03-25	Comstock MultiChain Fund, L P Engages with BNB Plus Corp	CI
02-12	BNB Plus Corp. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-05	BNB Plus Corp. Appoints James Haft as Independent Director and Nominating Committee Member, Effective February 2, 2026	CI
01-22	BNB Plus Corp. Announces Resignation of Director Elizabeth M. Schmalz Shaheen, Effective January 15, 2026	CI
01-05	BNB Plus Corp. Receives USD 1.2 Million Accelerated LineaDNA? Order	CI
01-05	Bnb Plus Corp receives $1.2M Accelerated Lineadna(TM) order	RE
12-22	BNB Plus Corp. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
12-18	BNB Plus Corp. Announces Largest Ever Shipment of LineaDNA	CI
11-17	Applied DNA rebrands as BNB Plus Corp., elects Josh Kruger as chairman of the board	RE

BNB Plus Corp., formerly Applied DNA Sciences, Inc., is a digital asset treasury (DAT) company that has adopted BNB, the native cryptocurrency of the Binance blockchain ecosystem, as its primary reserve asset. Its segments include digital asset treasury, therapeutic deoxyribonucleic acid (DNA) production services, DNA tagging and security products and services. Its digital asset treasury segment is engaged in managing digital assets. Its therapeutic DNA production services segment is engaged in nucleic-acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP and LineaIVT. Its DNA tagging and security products and services segment is engaged in the manufacture and detection of DNA for industrial supply chains and security services. Its subsidiary LineaRx, Inc., is engaged in commercializing nucleic acid production solutions for the biopharmaceutical and diagnostics markets.

Employees

Sector

Investment Management & Fund Operators

More about the company